Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24646019 | 0.84 | MAOB (0.50) | FFAR1MAOBKMT2ASMN1; SMN2BCHE | |
| SCHEMBL29454548 | 0.81 | SMN1; SMN2 (0.49) | FFAR1MAOBKMT2ASMN1; SMN2BCHE | |
| SCHEMBL22717572 | 0.81 | FFAR1 (0.53) | FFAR1MAOBKMT2ASMN1; SMN2BCHE | |
| SCHEMBL22724743 | 0.81 | SMN1; SMN2 (0.49) | FFAR1MAOBKMT2ASMN1; SMN2BCHE | |
| SCHEMBL24646025 | 0.81 | SMN1; SMN2 (0.49) | FFAR1MAOBKMT2ASMN1; SMN2BCHE | |
| SCHEMBL30211110 | 0.81 | FFAR1 (0.53) | FFAR1MAOBKMT2ASMN1; SMN2BCHE | |
| SCHEMBL28969185 | 0.81 | FFAR1 (0.53) | FFAR1MAOBKMT2ASMN1; SMN2BCHE | |
| SCHEMBL23923967 | 0.78 | BCHE (0.53) | FFAR1MAOBKMT2ASMN1; SMN2BCHE | |
| SCHEMBL23923970 | 0.78 | BCHE (0.53) | FFAR1MAOBKMT2ASMN1; SMN2BCHE | |
| SCHEMBL30317816 | 0.78 | BCHE (0.53) | FFAR1MAOBKMT2ASMN1; SMN2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| WO-2018081047-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | FFAR1 16/4885MAOB 2023/4885KMT2A 3114/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | FFAR1 16/4885MAOB 2023/4885KMT2A 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.